Navigation Links
MIS/AMH ELISA Test

ProductsMIS/AMH ELISA Test
Company Diagnostic Systems Laboratories, Inc.
Item MIS/AMH ELISA Test
Features Inquire
Description Mullerian Inhibiting Substance (MIS), also known as Anti-Mullerian Inhibiting Substance (AMH), is a glycoprotein dimer composed of two 72 kDa monomers linked by disulfide bridges (1). MIS/AMH belongs to the transforming growth factor-? (TGF-?) superfamily which includes TGF-? and the various inhibin and activin glycoproteins (2). All members of this superfamily are dimeric glycoproteins, and all are involved in the regulation of tissue growth and differentiation. The human gene coding for MIS/AMH has been sequenced and isolated, and is located on the short arm of chromosome 19 (3). The structure of a specific receptor for MIS/AMH has also been isolated and characterized (4).

MIS/AMH is produced by the Sertoli cells of the testis in the male, and by ovarian granulosa cells in the female. During embryonic development in males, secretion of MIS/AMH from testicular Sertoli cells is essential for the regression of the Mullerian ducts, and thus the normal development of the male reproductive tract (5). The Mullerian ducts are the primordium for the uterus, Fallopian tubes and upper vagina in the female. In the male, secretion of MIS/AMH by the Sertoli cells commences during embryogenesis and continues throughout life. Levels drop following puberty, decreasing slowly to a relatively low post-puberty value (2). In the female, serum MIS/AMH is undetectable using immunoassay until the onset of puberty. Thereafter, circulating MIS/AMH is maintained at relatively low levels until menopause, at which time MIS/AMH falls again to undetectable levels (as measured by immunoassay).

Potential clinical applications for a specific MIS/AMH assay include: the investigation of ovarian reserve and the perimenopausal transition in women; the detection and management of granulosa cell tumors; the diagnosis of precocious puberty and conversely, its delayed onset in the young; the differential diagnosis of intersex disorders; the diagnosis of cryptoorchidism and anorchidism, and the evaluation of male gonadal function at all ages (2).

  1. Picard JY, Josso N Mol Cell Endocrinol 34: 23-29, 1984.
  2. Teixeira J et al. Endocrine Reviews 22: 657-674, 2001.
  3. Picard JY et al. Proc Natl Acad Sci 83: 5464-5468, 1986.
  4. di Clemente N et al. Mol Endocrinol 8: 1006-1020, 1994.
  5. Picon R Arch Anat Microsc Morphol Exp 58: 1-19, 1969.
  6. Hudson PL et al. J Clin Endocrinol Metab 70: 16-22, 1990.
Info Diagnostic Systems Laboratories, Inc.
Customer Service: (800) 231-7970
Web site: http://www.dslabs.com

Related medicine products :

1. Microplate ELISA Washers - Manual Microplate Washer
2. Microplate ELISA Washers - Automated Microplate Washer
3. Vitamin D 25-Hydroxy ELISA 026-AC-57F1 Bone and Mineral Metabolism
4. RELISA ANA Screening System
5. BioCheck hCG ELISA
6. Human Chorionic Gonadotropin (HCG) ELISA Kit
7. Human PSA ELISA Kit
8. Total PSA ELISA Test
9. Free PSA ELISA
10. PAP Microwell ELISA
11. Trinity Biotech Captia™ B. burgdorferi IgG/IgM ELISA
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products:
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable ... and Fashion Show from 10:30 a.m. to noon on ... 2626 W. 63rd St. in Chicago, serves low-income older ... to maintain their independence. , “Mothers, grandmothers, godmothers and ... Day Brunch,” said Director of Marketing Elizabeth Clippard. , ...
(Date:4/27/2015)... Church, VA (PRWEB) April 28, 2015 ... Works, **Presented by FDAnews and Ombu Enterprises**, June 16-17, ... If an FDA inspector came to a facility today, ... , If the answer is "maybe" or "no" ... Ombu Enterprises and FDAnews have a solution. , ...
(Date:4/27/2015)... 2015 How to Implement UDI:, Lessons ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI ... of regulatory restraint, there’s plenty of time to get ... again. UDI deadlines are coming fast for all devicemakers ... Don’t delay, even if it seems there’s no rush. ...
(Date:4/27/2015)... April 28, 2015 Healthcare marketing ... paper called “Website Anatomy 101.” Available ... the necessary design elements for a successful hospital ... responsive design, user experience, search results and lead ... of a well-designed website on patient volume and ...
(Date:4/27/2015)... 2015 Women may have a more ... to a new study published online in the journal ... injury (MTBI), is a common medical problem affecting cognitive ... , In most cases, patients who experience MTBI will ... percent of MTBI patients will continue to experience persistent ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
... 3 America,s oldest voluntary health organization is led ... Elected National Board Chair, after more than a decade ... successfully steered the American Lung Association to tackle key ... of his chairmanship has been to build on the ...
... variation in exposure, depending on several factors, , , TUESDAY, ... widely among people who undergo computed tomography (CT) scans, ... in the Feb. 4 issue of the Journal ... after the American Heart Association urged that CT scans ...
... for Southeastern Michigan Screens Patients DETROIT, Feb. 3 ... Saturday, February 7, over 300 children from the Detroit ... of the American Dental Association,s seventh annual "Give Kids ... their services that day to children who, because of ...
... Reinforce Commitment to Safety Net Partnerships and Quality ... Kaiser Permanente announced today that ... totaling approximately $43 million in the fourth quarter ... Community Benefit grants in the fourth quarter focused ...
... Feb. 3 Nearly three out ... insurance should cover the cost of addiction treatment ... their own health insurance would pay for substance ... Toward Addiction Survey" from Hazelden, the national nonprofit ...
... NASHVILLE, Tenn., Feb. 3 Healthcare Realty Trust,Incorporated (NYSE: ... cash dividend for the,quarter ended December 31, 2008. ... payable on March 5, 2009 to shareholders of record ... Realty Trust is a real estate investment trust that ...
Cached Medicine News:Health News:Maryland Lawyer Steve Nolan Advocates for Lung Health as National Board Chair of the American Lung Association 2Health News:Radiation From CT Scans Not Always the Same 2Health News:Radiation From CT Scans Not Always the Same 3Health News:Area Dentists, University of Detroit Mercy Team Up to Provide Free Dental Care to Low-Income, Uninsured Detroit-Area Children on Saturday, February 7 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 2Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 3Health News:Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008 4Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., ... for curative treatment of chronic hepatitis B virus (HBV) ... for its lead HBV core inhibitor candidate, NVR 3-778, ... for the Study of the Liver (EASL) in ... activity of NVR 3-778 from studies performed in a ...
(Date:4/27/2015)... BRH Medical, Ltd., today announced that it ... (510k) with the US Food and Drug Administration (FDA) ... feedback from the FDA during the next quarter and ... pre-market clearance. Additional pre-market regulatory filings are anticipated during ... BRH Medical, commented, "We are thrilled to have reached ...
(Date:4/27/2015)... 2015 Endo International plc (NASDAQ: ENDP ) ... before the open of the U.S. financial markets on May ... host a conference call and webcast at 9:00 a.m. ET ... the call is U.S./ Canada (866) 497-0462, ... dial in 10 minutes prior to the scheduled start time. ...
Breaking Medicine Technology:Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2